Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip K Knop

Showing results (101-110 of 434) with videos related to

Pageof 44
Sort By:
The Journal of Clinical Endocrinology and Metabolism|February 10, 2012
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjectsKatrine B Hansen, Tina Vilsbøll, Jonatan I Bagger, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metforminEmilie Bahne, Morten Hansen, Andreas Brønden, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 22, 2021
Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinicKatrine B Hansen, Mathilde Svendstrup, Asger Lund, et al.
BMC Research Notes|June 3, 2014
Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case reportFilip K Knop, Asger Lund, Sten Madsbad, et al.
Diabetes, Obesity & Metabolism|March 25, 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetesJohn B Buse, Ingrid Holst, Filip K Knop, et al.
JOP : Journal of the Pancreas|September 7, 2010
The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiencyFilip K Knop, Tina Vilsbøll, Asger Lund, et al.
European Journal of Endocrinology|July 3, 2014
Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1David P Sonne, Jens F Rehfeld, Jens J Holst, et al.
Frontiers in Endocrinology|November 22, 2018
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLDMarta Seghieri, Alexander S Christensen, Andreas Andersen, et al.
Diabetes Care|August 28, 2003
No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitisFilip K Knop, Tina Vilsbøll, Steen Larsen, et al.
BMJ Open|October 6, 2018
Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trialAlexander Sidelmann Christensen, Heidi Storgaard, Sofie Hædersdal, et al.
Pageof 44

Showing results (101-110 of 434) with videos related to

Sort By:
Pageof 44
The Journal of Clinical Endocrinology and Metabolism|February 10, 2012
Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjectsKatrine B Hansen, Tina Vilsbøll, Jonatan I Bagger, et al.
Diabetes, Obesity & Metabolism|June 7, 2016
Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metforminEmilie Bahne, Morten Hansen, Andreas Brønden, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|July 22, 2021
Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinicKatrine B Hansen, Mathilde Svendstrup, Asger Lund, et al.
BMC Research Notes|June 3, 2014
Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case reportFilip K Knop, Asger Lund, Sten Madsbad, et al.
Diabetes, Obesity & Metabolism|March 25, 2021
Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetesJohn B Buse, Ingrid Holst, Filip K Knop, et al.
JOP : Journal of the Pancreas|September 7, 2010
The impact of pancreatic enzyme supplementation on postprandial responses of glucagon-like Peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiencyFilip K Knop, Tina Vilsbøll, Asger Lund, et al.
European Journal of Endocrinology|July 3, 2014
Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1David P Sonne, Jens F Rehfeld, Jens J Holst, et al.
Frontiers in Endocrinology|November 22, 2018
Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLDMarta Seghieri, Alexander S Christensen, Andreas Andersen, et al.
Diabetes Care|August 28, 2003
No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitisFilip K Knop, Tina Vilsbøll, Steen Larsen, et al.
BMJ Open|October 6, 2018
Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trialAlexander Sidelmann Christensen, Heidi Storgaard, Sofie Hædersdal, et al.
Pageof 44